Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies
Emmanuelle Weiller,1 Catherine Weiss,2 Christopher P Watling,3 Christopher Edge,3 Mary Hobart,2 Hans Eriksson,1 Maurizio Fava4–6 1H. Lundbeck A/S, Valby, Copenhagen, Denmark; 2Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA; 3Cambridge Medical Commun...
Guardado en:
Autores principales: | Weiller E, Weiss C, Watling CP, Edge C, Hobart M, Eriksson H, Fava M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/abdfed5f9cc94204b7f923f86fe3c5ef |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies
por: Thase ME, et al.
Publicado: (2018) -
Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trials
por: Durgam S, et al.
Publicado: (2016) -
Does Subjective Cognitive Function Mediate the Effect of Affective Temperaments on Functional Disability in Japanese Adults?
por: Toyoshima K, et al.
Publicado: (2020) -
Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: a meta-analysis of randomized controlled trials
por: Luan SX, et al.
Publicado: (2018) -
Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi T, et al.
Publicado: (2017)